Anti-IL11 treatment blocks the Erk and Smad pathways to inhibit the activation of lung fibroblasts, thereby alleviating lung inflammation and reversing bleomycin-induced pulmonary fibrosis [39]. This evidence concerns the gene IL11 and pulmonary fibrosis.